Six days. That is roughly how long it takes half a dose of lutetium-177 to decay into something useless for treating cancer. Hospitals cannot stockpile it. They need a fresh batch on a tight schedule, or a patient’s treatment slips.
On November 11, 2026, Oklo Inc. announced that the U.S. Department of Energy cleared the final operations hold point for its Groves-1 test reactor near Lockhart, Caldwell County, Texas. The clearance does not make medicine yet. It moves the reactor into a research, testing, and training phase, the next formal step toward a future isotope supply chain.
What DOE Just Cleared for the Groves-1 Test Reactor
The clearance lets Groves-1, officially the Groves Isotope Test Reactor, run under what DOE calls unrestricted operations. That is a research and demonstration authorization, not a commercial power license. The Nuclear Regulatory Commission still reviews commercial reactor designs. DOE’s authority here comes from the Atomic Energy Act, which lets the agency approve reactors built for research, development, and demonstration, including ones built on private land under its own program.
Groves-1 is one of 11 advanced reactor projects DOE selected in August 2025 for its Reactor Pilot Program. The program grew out of May 2025 executive orders calling for at least three prototype reactors to reach criticality by July 4, 2026. Groves-1 got there in August 2026, Oklo’s first reactor built under the program on private land, and by the company’s account, less than a year after it broke ground. Oklo did not give the exact groundbreaking date.
From Test Reactor to Training Platform
With the clearance in hand, Groves-1’s job changes. Oklo plans to use it to train and qualify nuclear operating personnel, test control rod drive mechanism performance and reliability, and run human machine interface studies, including eye tracking glasses that watch how operators actually work the controls. The reactor will also support criticality and reactivity benchmarking that feeds data back into isotope production models and, potentially, light water reactor design work.
“Taking Groves-1 from greenfield to criticality in less than a year” is how Oklo co-founder and CEO Jacob DeWitte described the milestone, pointing to it as proof of what his team can build and run. Chimi Zacot, DOE’s acting deputy assistant secretary for nuclear reactors, said successes like Groves-1’s criticality are paving the way for what comes next.
So Is This Reactor Making Cancer Medicine Yet?
No. Groves-1 trains people and tests equipment. It does not produce isotopes for patients. That job is planned for a separate facility that has not been built yet, called Groves-2 Forge, an isotope production and processing pilot plant selected under DOE’s Nuclear Energy Launch Pad initiative. Groves-2 Forge would pair reactor irradiation with hot cell processing: separating isotopes, recovering the product, packaging it, and shipping it out. Its first target is lutetium-177, the same short lived isotope used in targeted radioligand cancer therapies.
Oklo has not announced a construction timeline, cost, or opening date for Groves-2 Forge. What exists today is Groves-1’s operating data, which the company says will inform how that future isotope facility gets designed and run, along with testing that also feeds Oklo’s separate Aurora fast fission powerhouse program, the same reactor line behind Oklo’s recent HALEU fuel supply deal for its planned Ohio campus.
Why It Matters to You
- Lutetium-177 already treats certain prostate and neuroendocrine cancers today, and supply has been tight before. A widely reported Novartis shortage of its Pluvicto radioligand treatment left some patients waiting for doses in recent years.
- Nothing about this week’s news changes that supply today. Groves-1 is a test and training reactor, not a production line.
- Groves-2 Forge, the facility actually meant to make lutetium-177, has no construction date, cost estimate, or opening target yet.
- If it is eventually built, a second domestic isotope source could someday mean fewer shortages and shorter waits for patients on this therapy, but that outcome is years off and not guaranteed.
What’s Not Confirmed Yet
- No groundbreaking date, construction cost, or timeline has been released for Groves-2 Forge, the facility that would actually produce lutetium-177.
- Groves-1’s clearance is a DOE research and demonstration authorization, not an NRC commercial license, and it does not extend to any future commercial isotope or power reactor Oklo might build.
- Oklo has not said when, or whether, the control rod and interface testing at Groves-1 will lead to design changes elsewhere, including its Aurora powerhouse program.
A test reactor clearing its final hold point in a small Texas county will not make headlines outside the nuclear press. But isotope supply chains tend to be invisible until they break. The real question is not whether Groves-1 works. It already does. It is whether Groves-2 Forge ever gets a groundbreaking date of its own.
Sources
- Oklo Inc., “Oklo’s Groves-1 to Begin Research and Demonstration Phase After Being Cleared by U.S. Department of Energy,” November 11, 2026.
- World Nuclear News, “US test reactor cleared for operations,” November 12, 2026.